Alpine Immune Sciences (NASDAQ:ALPN) Sets New 52-Week High at $64.72

Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $64.72 and last traded at $64.70, with a volume of 748953 shares changing hands. The stock had previously closed at $64.64.

Analyst Ratings Changes

A number of analysts have commented on ALPN shares. Guggenheim started coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They set a "buy" rating and a $55.00 price target on the stock. Wedbush downgraded Alpine Immune Sciences from an "outperform" rating to a "neutral" rating in a research report on Thursday, April 11th. Morgan Stanley reiterated an "equal weight" rating and set a $65.00 price target (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. HC Wainwright lowered Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a report on Thursday, April 11th. Finally, Wolfe Research reaffirmed a "peer perform" rating on shares of Alpine Immune Sciences in a report on Thursday, April 11th. Eight investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Alpine Immune Sciences currently has a consensus rating of "Hold" and an average target price of $50.33.

Alpine Immune Sciences Price Performance

The firm has a market capitalization of $4.24 billion, a PE ratio of -101.09 and a beta of 0.97. The firm has a fifty day moving average price of $48.01 and a 200 day moving average price of $29.53.

Alpine Immune Sciences (NASDAQ:ALPN - Get Free Report) last posted its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of ($0.32) by $0.47. The company had revenue of $30.85 million during the quarter, compared to analyst estimates of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. On average, sell-side analysts expect that Alpine Immune Sciences, Inc. will post -1.74 EPS for the current year.

Hedge Funds Weigh In On Alpine Immune Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new stake in shares of Alpine Immune Sciences in the first quarter valued at $27,000. Allspring Global Investments Holdings LLC raised its position in Alpine Immune Sciences by 745.5% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,312 shares during the period. AJOVista LLC purchased a new stake in Alpine Immune Sciences in the 4th quarter worth about $64,000. Barclays PLC boosted its position in Alpine Immune Sciences by 44.3% during the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company's stock worth $104,000 after acquiring an additional 2,801 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Alpine Immune Sciences by 411.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,490 shares of the biotechnology company's stock valued at $105,000 after acquiring an additional 4,417 shares in the last quarter. Institutional investors and hedge funds own 75.17% of the company's stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.